Compare Mesoblast Limited (MESO) vs Match Group Inc (MTCH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Match Group Inc — how do they compare? Mesoblast Limited trades at $16.68 (market cap $2.16B), while Match Group Inc trades at $36.82 (market cap $8.43B). The key difference: Match Group Inc is far larger — about 3.9× Mesoblast Limited's market cap, and Match Group Inc pays a 2.18% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | MTCH | |
|---|---|---|
Market Cap | $2.16B | $8.43B |
Sector | Technology | Media |
52-Week High | $20.96 | $41.24 |
52-Week Low | $12.88 | $28.90 |
Enterprise Value | $2.17B | $11.40B |
Dividend Yield | — | 2.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $15.94, up 2.05% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Ryoncil net revenues of $36 million for Q2 2026 (GlobeNewsWire, July 29, 2026), showing commercial traction, yet fundamentals reveal a net loss of -$102.14 million in 2025 with a negative net margin. Valuation metrics include a P/S of 30.52 and P/B of 3.76, indicating high growth expectations.
Outlook hinges on Ryoncil's expansion and pipeline progress, but risks include sustained losses and regulatory hurdles. Analysts are cautiously optimistic with 45% buy ratings, yet the stock faces volatility from earnings misses and high cash burn.
MTCH trades at $37.26, up 1.78% on the day, with a bearish technical signal and neutral oscillators. The stock shows mixed earnings performance, beating Q2 2026 EPS estimates but missing on revenue, as Tinder faces headwinds while Hinge grows. Strong profitability is evident with a 74.8% gross margin and 20.17% net income margin, though high debt levels remain a concern. Recent news highlights institutional buying interest amid ongoing business transformation.
The outlook is cautiously optimistic, supported by a consensus price target of $42.33 (13.6% upside) and no sell ratings. Key opportunities include Hinge's international expansion and Tinder's turnaround potential, but risks involve execution challenges, competitive pressures, and significant leverage. Earnings growth remains the primary catalyst for valuation re-rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Match Group Inc
Match Group is a provider of online dating products. The firm became public in 2015 and was more than 80% owned by IAC/InterActiveCorp until IAC spun it off in the second quarter of 2020. The company has a vast portfolio of different online dating service providers, including Tinder, Match.com, OkCupid, Plenty of Fish, and Meetic. Match Group has more than 45 brands of online dating sites and/or apps, from which it generates user fee revenue (95%) and advertising revenue (5%).
Read more on MTCH →
